SCHEMBL802133 — predicted protein targets

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	IGF1R	P08069	3/20	0.42

▸	CYP1A2	P05177	3/20	0.41

▸	CYP2C19	P33261	2/20	0.41

▸	AURKA	O14965	8/20	0.41

▸	AURKB	Q96GD4	4/20	0.41

▸	SRC	P12931	2/20	0.41

▸	GSK3B	P49841	2/20	0.41

▸	EIF2AK2	P19525	1/20	0.41

▸	GSK3A	P49840	1/20	0.41

▸	ADRB2	P07550	1/20	0.39

▸	HTR1B	P28222	1/20	0.39

▸	HTR2A	P28223	1/20	0.39

▸	HTR2C	P28335	1/20	0.39

▸	HTR2B	P41595	1/20	0.39

▸	SYK	P43405	1/20	0.39

▸	NTRK1	P04629	1/20	0.38

▸	DHODH	Q02127	1/20	0.38

▸	CYP2D6	P10635	1/20	0.38

▸	RECQL	P46063	1/20	0.38

▸	JAK2	O60674	1/20	0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL13962814	0.85	IGF1R (0.42)	IGF1RAURKAAURKBSRCGSK3B
SCHEMBL13055041	0.78	IGF1R (0.39)	IGF1RAURKAAURKBSRCGSK3B
SCHEMBL802128	0.78	USP1 (0.42)	CYP1A2CYP2C19GSK3BGSK3AHTR2A
SCHEMBL802434	0.78	AURKA (0.68)	CYP1A2CYP2C19AURKAAURKBSRC
SCHEMBL10186379	0.76	DHODH (0.49)	IGF1RAURKAAURKBSRCGSK3B
SCHEMBL10185784	0.76	AURKA (0.58)	IGF1RAURKAAURKBSRCGSK3B
SCHEMBL801822	0.75	GSK3A (0.41)	IGF1RCYP1A2CYP2C19GSK3BGSK3A
SCHEMBL801898	0.74	PIP4K2C (0.56)	CYP1A2CYP2C19AURKAAURKBSRC
SCHEMBL10267534	0.74	AURKA (0.46)	CYP1A2CYP2C19AURKAAURKBSRC
SCHEMBL12619093	0.74	AURKA (0.46)	IGF1RCYP1A2CYP2C19AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-8633210-B2	Triazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2014-01-21	—	—	US	disclosed
US-8633210-B2	Triazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2014-01-21	—	—	US	disclosed
US-8524720-B2	Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2013-09-03	—	—	US	disclosed
US-8524720-B2	Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2013-09-03	—	—	US	disclosed
US-20120071657-A1	TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS	VERTEX PHARMACEUTICALS INCORPORATED (US)	2012-03-22	—	—	US	disclosed
US-20120071657-A1	TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS	VERTEX PHARMACEUTICALS INCORPORATED (US)	2012-03-22	—	—	US	disclosed
US-7951820-B2	Triazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2011-05-31	—	—	US	disclosed
US-7951820-B2	Triazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2011-05-31	—	—	US	disclosed
US-20100256170-A1	PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS	VERTEX PHARMACEUTICALS INCORPORATED (US)	2010-10-07	—	—	US	disclosed
US-20100256170-A1	PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS	VERTEX PHARMACEUTICALS INCORPORATED (US)	2010-10-07	—	—	US	disclosed
US-7691853-B2	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2010-04-06	—	—	US	disclosed
US-7691853-B2	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2010-04-06	—	—	US	disclosed
US-7390815-B2	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2008-06-24	—	—	US	disclosed
US-7390815-B2	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2008-06-24	—	—	US	disclosed
US-20070270444-A1	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED	2007-11-22	—	—	US	disclosed
US-20070270444-A1	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED	2007-11-22	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20100256170-A1	PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS	GSK3B, CDK3, GSK3A	IGF1R 540/4885CYP1A2 1818/4885CYP2C19 2691/4885
US-20120071657-A1	TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS	GSK3B, GSK3A, CDK19	IGF1R 293/4885CYP1A2 3042/4885CYP2C19 1702/4885
US-20070270444-A1	Pyrazole compounds useful as protein kinase inhibitors	GSK3B, CDK3, GSK3A	IGF1R 540/4885CYP1A2 1818/4885CYP2C19 2691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.